Sledovat
Helena Peschelová
Helena Peschelová
E-mailová adresa ověřena na: mail.muni.cz
Název
Citace
Citace
Rok
Genomewide profiling of copy‐number alteration in monoclonal gammopathy of undetermined significance
A Mikulasova, J Smetana, M Wayhelova, H Janyskova, V Sandecka, ...
European journal of haematology 97 (6), 568-575, 2016
322016
CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells
V Kozlova, A Ledererova, A Ladungova, H Peschelova, P Janovska, ...
PLoS One 15 (3), e0229170, 2020
122020
Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia
V Mancikova, H Peschelova, V Kozlova, A Ledererova, A Ladungova, ...
Journal for immunotherapy of cancer 8 (1), 2020
112020
Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro
A Ledererova, L Dostalova, V Kozlova, H Peschelova, A Ladungova, ...
Journal for immunotherapy of cancer 9 (8), 2021
62021
Identification of a family with SUFU germline deletion based on a case of desmoplastic medulloblastoma in an infant
J Šoukalová, K Vejmělková, T Cermanová, K Kašíková, A Mikulášová, ...
Klinicka Onkologie: Casopis Ceske a Slovenske Onkologicke Spolecnosti 29, S83-8, 2016
32016
Lyn Phosphorylates and Controls ROR1 Surface Dynamics During Chemotaxis of CLL Cells
Z Dave, OV Blanářová, Š Čada, P Janovská, N Zezula, M Běhal, ...
Frontiers in cell and developmental biology 10, 2022
12022
Whole genome amplification effect on segmental copy-number changes and copy-number neutral loss of heterozygosity analysis by oligonucleotide-array based comparative genomic …
A Mikulášová, J Smetana, M Wayhelová, H Peschelová, SA Okubote, ...
12016
CD19 promoter hypermethylation as means of antigen-negative escape to CART-19 therapy.
L Dostálová, A Ledererová, V Kozlová, H Peschelová, A Ladungová, ...
2021
Drug repositioning in genetically defined CLL cases reveals a potentional novel therapeutic use for approved drugs.
A Ladungová, H Peschelová, V Kozlová, M Šmída
2021
In vivo antigen-negative escape to CART-19 caused by CD19 promotor hypermethylation.
L Dostálová, A Ledererová, V Kozlová, H Peschelová, A Ladungová, ...
2021
CRISPR/CAS9 technology: a useful tool in the study of chronic lymphocytic leukemia
H Peschelová, V Kozlová, V Mančíková, A Ladungová, V Hejret, M Šmída
2020
Impact of genetics on the performance of anti-CD 19 chimeric antigen receptor T cells in chronic lymphocytic leukemia
V Mančíková, V Kozlová, H Peschelová, J Mayer, Š Pospíšilová, M Šmída
2020
Genome-wide CRISPR/Cas9 screening reveals novel target genes, whose inactivation is able to upregulate surface expression of immunotherapy target CD20
H Peschelová, L Dostálová, V Kozlová, A Ledererová, V Hejret, M Šmída
2020
Combination of epigenetic drug screen and CRISPR knockout screen revealed involvement of aurora kinases and Cullin 3 in CD20 regulation
A Ledererová, V Kozlová, V Mančíková, H Peschelová, J Persson, ...
2020
The use of CRISPR/Cas9 technology in the study of chronic lymphocytic leukemia.
H Peschelová, V Kozlová, V Mančíková, A Ladungová, V Hejret, M Šmída
2020
Lyn controls chemotaxis and motility of CLL cells via phosphorylation of ROR1
Z Dave, OV Blanářová, Š Čada, P Janovská, N Zezula, M Běhal, ...
bioRxiv, 2020
2020
CRISPR/Cas9 gene editing and functional screening in chronic lymphocytic leukemia
H Peschelová, V Kozlová, V Hejret, M Šmída
2019
CRISPR/Cas9-mediated gene knockout of TP53 and ATM in HG3 cell line: models for chronic lymphocytic leukemia
H Peschelová, V Kozlová, Š Pospíšilová, M Šmída
2018
ZPRÁVY Z VĚDECKÉHO ŽIVOTA
A Táborský, H Janyšková
Systém momentálně nemůže danou operaci provést. Zkuste to znovu později.
Články 1–19